VEGFR2 CAR T

Fatemeh Hajari Taheri1,2, Mahmoud Hassani3,4, Zahra Sharifzadeh1

  • 1Hybridoma Lab, Department of Immunology, Pasteur Institute of Iran, Tehran, Iran.

BMC biotechnology
|January 4, 2024
PubMed
概括

优化化学抗原受体 (CAR-T) 细胞用于癌症免疫疗法至关重要. 在VEGFR2-CAR T细胞中的更长的细胞外间隔器增强了它们的抗癌活性和固体瘤治疗的潜力.

相关概念视频